Short-term brain atrophy changes in relapsing-remitting multiple sclerosis

被引:35
|
作者
Zivadinov, R
Bagnato, F
Nasuelli, D
Bastianello, S
Bratina, A
Locatelli, L
Watts, K
Finamore, L
Grop, A
Dwyer, M
Catalan, M
Clemenzi, A
Millefiorini, E
Bakshi, R
Zorzon, M
机构
[1] Univ Trieste, Dept Clin Med & Neurol, Trieste, Italy
[2] SUNY Buffalo, Dept Neurol, Jacobs Neurol Inst, Buffalo Neuroimaging Anal Ctr, Buffalo, NY 14203 USA
[3] Univ Roma La Sapienza, Dept Neurol Sci, Rome, Italy
[4] Univ Pavia, IRCCS C Mondino, Dept Neuroradiol, Pavia, Italy
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ctr Neurol Imaging,Partners Multiple, Boston, MA USA
关键词
multiple sclerosis; MRI; brain atrophy; short-term changes; ring enhancement;
D O I
10.1016/j.jns.2004.05.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this study was to establish whether the time interval of 3 months is sufficient to detect whole-brain atrophy changes in patients with relapsing-remitting (RR) multiple sclerosis (MS). Another aim was to assess the value of monthly gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) and of different Gd-enhancement patterns as predictors of brain atrophy. Thirty patients with RRMS (mean disease duration 4.9 years, mean age 34.4 years and mean Expanded Disability Status Scale [EDSS] 1.4) were assessed at baseline and monthly for a period of 3 months with clinical and MRI examinations. Calculations of baseline and monthly absolute and percent changes of MRI measures have been obtained using two semiautomated (Buffalo and Trieste) and one automated (SPM99) segmentation method. Changes of brain parenchymal fraction (BPF) were investigated according to Gd-enhancement patterns. Mean absolute and percent changes of BPF did not significantly differ at any time point of the study for any of the three methods. There was slight but not significant decrease of BPF from baseline to month 3: - 0.0004 (0.05%), p = 0.093 for Trieste; - 0.0006 (0.07%), p = 0.078 for Buffalo; and - 0.0006 (0.08%), p = 0.081 for SPM99 method. In ring-enhancement positive patients, there was a significant difference between baseline and month 3 changes of BPF, EDSS, and number of relapses. Over the study period, we did not demonstrate differences between changes of BPF according to the presence of Gd enhancement. Longitudinally, multiple regression analysis demonstrated that the only clinical or MRI parameter that predicted BPF decrease was the mean absolute change of ring-enhancing lesion load (R = 0.62, p = 0.003). The noteworthy findings of this study are (1) the observation that a significant brain atrophy progression cannot be detected over a 3-month period in RRMS; (2) the demonstration that the ring-enhancement pattern may contribute to more severe brain tissue loss in the short term; and (3) the lack of relationship between the presence and duration of Gd-enhancement activity and brain volume changes in the short term. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:185 / 193
页数:9
相关论文
共 50 条
  • [1] Short-term prognosis in relapsing-remitting multiple sclerosis
    Diaz-Sanchez, M.
    Alvarez-Cermeno, J. C.
    Garcia-Barragan, N.
    Sadaba, M. C.
    Masjuan, J.
    Espino, M.
    Gomez-Rial, J.
    Gonzalez-Porque, P.
    Muriel, A.
    Villar, L. M.
    [J]. MULTIPLE SCLEROSIS, 2006, 12 : S89 - S89
  • [2] Short-term prognosis in early relapsing-remitting multiple sclerosis
    Scott, TF
    Schramke, CJ
    Novero, J
    Chieffe, C
    [J]. NEUROLOGY, 2000, 55 (05) : 689 - 693
  • [3] Short-term exposure to cyclophosphamide is effective in reducing long-term brain atrophy in refractory relapsing-remitting multiple sclerosis
    Perumal, J.
    Bao, F.
    Latif, Z.
    Zak, I.
    Caon, C.
    Tselis, A.
    Khan, O.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S246 - S246
  • [4] The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis
    Borges, Isabela T.
    Shea, Colin D.
    Ohayon, Joan
    Jones, Blake C.
    Stone, Roger D.
    Ostuni, John
    Shiee, Navid
    McFarland, Henry
    Bielekova, Bibiana
    Reich, Daniel S.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (02) : 133 - 140
  • [5] Brain atrophy in clinically early relapsing-remitting multiple sclerosis
    Chard, DT
    Griffin, CM
    Parker, GJM
    Kapoor, R
    Thompson, AJ
    Miller, DH
    [J]. BRAIN, 2002, 125 : 327 - 337
  • [6] Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Costa Arpin, Eva
    Garcia Sobrino, Tania
    Dominguez Vivero, Clara
    Amigo Jorrin, Maria del Campo
    Rodriguez Regal, Ana
    Prieto Gonzalez, Jose
    Lema Bouzas, Manuela
    [J]. NEURODEGENERATIVE DISEASE MANAGEMENT, 2016, 6 (01) : 5 - 12
  • [7] Brain atrophy is age-related in relapsing-remitting multiple sclerosis
    Kacar, Sezgi
    Coerver, Eline
    Schoonheim, Menno
    Koch, Marcus
    Mostert, Jop
    Killestein, Joep
    Sormani, Maria Pia
    Ciccarelli, Olga
    Arnold, Douglas L.
    Barkhof, Frederik
    Uitdehaag, Bernard
    Eshaghi, Arman
    Strijbis, Eva
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 13 - 14
  • [8] Short-term brain volume change in relapsing-remitting multiple sclerosis - Effect of glatiramer acetate and implications
    Rovaris, M
    Comi, G
    Rocca, MA
    Wolinsky, JS
    Filippi, M
    [J]. BRAIN, 2001, 124 : 1803 - 1812
  • [9] Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy
    Vidal-Jordana, Angela
    Sastre-Garriga, Jaume
    Rovira, Alex
    Montalban, Xavier
    [J]. JOURNAL OF NEUROLOGY, 2015, 262 (12) : 2617 - 2626
  • [10] Effect of intravenous methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis
    Zivadinov, R
    Rudick, RA
    De Masi, R
    Nasuelli, D
    Ukmar, M
    Pozzi-Mucelli, RS
    Grop, A
    Cazzato, G
    Zorzon, M
    [J]. NEUROLOGY, 2001, 56 (08) : A192 - A192